Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9 3 and ABCC2 -24C T variants: a case report
2014 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9 3 and ABCC2 -24C T variants: a case report
Meyer zu Schwabedissen, H. E.; Siegmund, W.; Kroemer, H. K. & Rollnik, J. D. (2014)
BMC Research Notes, 7(688) art. 688. DOI: https://doi.org/10.1186/1756-0500-7-688
Documents & Media
Details
- Authors
- Meyer zu Schwabedissen, Henriette Elisabeth; Siegmund, Werner; Kroemer, Heyo Klaus ; Rollnik, Jens D.
- Abstract
- BACKGROUND: Genetic factors as predictor of the individual outcome of drug therapy is one aim of personalized medicine approaches. CASE PRESENTATION: We report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient receiving fluvastatin and telmisartan experiencing myotoxicity (myalgia and moderate creatine kinase elevation). CONCLUSIONS: The obtained findings suggest that heterocygocity of cytochrome P450 CYP2C9 3 variant in combination with multidrug resistance-associated protein MRP2-24C > T functions as risk factor predisposing to experience drug-drug interaction combing those drugs.
- Issue Date
- 2014
- Journal
- BMC Research Notes
- eISSN
- 1756-0500
- Language
- English
